SecBot SecBot
PRESS-RELEASE ·Filed Jul 7, 2026

AXSM

Axsome Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor for top-line data from the FOCUS-2 trial (timeline undisclosed). No near-term revenue or regulatory catalyst, solriamfetol is already in earlier-stage ADHD trials, so this is an incremental step. The stock likely sees limited reaction to a dosing announcement alone.

DirectionNeutral
Confidencemedium
Horizonmonths

solriamfetol

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and marketed (Sunosi, FDA-approved 2019)
Next catalyst
None dated

What to watchSolriamfetol is a steady commercial contributor (~$125M FY2025, 32% YoY) with patent protection through 2040, but it is not Axsome's primary growth driver, Auvelity is larger (~$291M in 2024) and just won an Alzheimer's agitation approval. Watch for whether Axsome files an ADHD sNDA in 2H 2026 or 2027, which would create a new regulatory catalyst. Until then, solriamfetol's value is in its reliable cash flow and pipeline-expansion optionality.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$249.76
T+0 close · Jul 7, 2026 · via day close
Latest settled
−26.17%
T+60 · $184.39
Vs SPY
−28.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 7 $249.76entry
  2. T+1 · 4mo ago −1.68%α −1.37% · $245.57
  3. T+5 · 4mo ago −5.81%α −6.36% · $235.26
  4. T+20 · 4mo ago −15.50%α −16.84% · $211.04
  5. T+60 · 7w ago −26.17%α −28.38% · $184.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, a 468-patient placebo-controlled study. This is a pipeline-progression event that extends the solriamfetol ADHD program into a younger pediatric population, but no efficacy data or commercial timelines were provided. The event is positive for the pipeline narrative but lacks financial impact or near-term catalyst.

Key Facts

  • First patient dosed in FOCUS-2 Phase 3 trial evaluating solriamfetol for children aged 6 to <12 with ADHD
  • Trial is randomized, double-blind, placebo-controlled; ~468 patients randomized 1:1:1 to one of two solriamfetol doses or placebo for 6 weeks
  • Primary endpoint: change from baseline to week 6 on ADHD-RS-5 total score
  • Previously Axsome initiated FOCUS-3 Phase 3 trial of solriamfetol in adolescents (12 to <18) with ADHD
  • No financial terms, cash runway implications, or timeline for data readout disclosed in the release

Financial Impact

No financial figures disclosed; pipeline expansion has no near-term revenue impact

Risk Factors

  • Phase 3 trial could fail on primary endpoint (ADHD-RS-5), which would impair solriamfetol's ADHD label expansion potential
  • Regulatory pathway in pediatric ADHD is untested for solriamfetol; safety and efficacy data required
  • Competition from existing ADHD treatments (stimulants, non-stimulants) may limit commercial opportunity even if approved

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3323028

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Viewing Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026